Literature DB >> 11120954

Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

C Lass-Flörl1, M Nagl, C Speth, H Ulmer, M P Dierich, R Würzner.   

Abstract

The minimal fungicidal concentrations (MFCs) of voriconazole and itraconazole for five clinical isolates each of Aspergillus terreus, Aspergillus fumigatus, Aspergillus flavus, and Aspergillus niger were determined by a broth macrodilution method. Conidial suspensions as inocula were compared to hyphae as inocula since the invasive form of aspergillosis is manifested by the appearance of hyphal structures. In addition, cell viability staining with the dye FUN-1 was performed to assess time-dependent damage of hyphae exposed to various concentrations of the antifungal agents. With conidial inocula the MFC ranges of voriconazole were 0.5 to 4 microg/ml and those of itraconazole were 0.25 to 2 microg/ml, whereas the MFCs (2 to >16 microg/ml) with hyphal inocula were substantially higher (P < 0.01) for both itraconazole and voriconazole. Only minor differences between the tested antifungals were observed since 16 of 20 and 17 of 20 of the isolates of Aspergillus spp. tested appeared to be killed by voriconazole and itraconazole, respectively. The results of FUN-1 viability staining correlated closely to colony counts, but various time- and dose-dependent levels of viability of hyphae were also observed. In conclusion, our study demonstrates the importance of the type of inoculum used to test antifungals and the applicability of FUN-1 staining as a rapid and sensitive method for assaying the viability of hyphae.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11120954      PMCID: PMC90249          DOI: 10.1128/AAC.45.1.124-128.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

Review 2.  Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation.

Authors:  T J Walsh; P A Pizzo
Journal:  Annu Rev Microbiol       Date:  1988       Impact factor: 15.500

3.  Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia.

Authors:  C R Bradford; A G Prentice; D W Warnock; J A Copplestone
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

Review 4.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

5.  Disseminated Aspergillus terreus infection in immunocompromised hosts.

Authors:  K S Hara; J H Ryu; J T Lie; G D Roberts
Journal:  Mayo Clin Proc       Date:  1989-07       Impact factor: 7.616

6.  Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents.

Authors:  E K Manavathu; J Cutright; P H Chandrasekar
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 7.  Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host.

Authors:  D W Denning
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

Review 8.  Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts.

Authors:  D M Tritz; G L Woods
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

9.  A prospective study of infectious diseases following bone marrow transplantation: emergence of Aspergillus and Cytomegalovirus as the major causes of mortality.

Authors:  P K Peterson; P McGlave; N K Ramsay; F Rhame; E Cohen; G S Perry; A I Goldman; J Kersey
Journal:  Infect Control       Date:  1983 Mar-Apr

10.  Pulmonary aspergillosis in the acquired immunodeficiency syndrome.

Authors:  D W Denning; S E Follansbee; M Scolaro; S Norris; H Edelstein; D A Stevens
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

View more
  25 in total

1.  Early events in macrophage killing of Aspergillus fumigatus conidia: new flow cytometric viability assay.

Authors:  K A Marr; M Koudadoust; M Black; S A Balajee
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.

Authors:  Rama Ramani; Madhurama Gangwar; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 4.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

7.  Voriconazole: the newest triazole antifungal agent.

Authors:  Nickie D Greer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-04

8.  In vitro activities of amphotericin B and voriconazole against aleurioconidia from Aspergillus terreus.

Authors:  Cornelia Lass-Flörl; Alexandra Rief; Sandra Leitner; Cornelia Speth; Reinhard Würzner; Manfred P Dierich
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.

Authors:  Russell E Lewis; Nathan P Wiederhold; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

10.  Conidial viability assay for rapid susceptibility testing of Aspergillus species.

Authors:  S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.